VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LFST
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LFSTLifeStance Health Group, Inc.
$13.77$5.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. LFST
  4. Financial Ratios

LifeStance Health Group, Inc. (LFST) Financial Ratios

Latest Ratios: P/E Ratio 74.9x · EV/EBITDA 33.0x · ROE 0.7%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

LFST Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$5.3B$2.8B$2.8B$2.9B$1.8B$3.1B——
Enterprise Value$5.3B$2.7B$3.1B$3.3B$2.1B$3.1B——
P/E Ratio →74.92352.00——————
P/S Ratio3.181.932.232.732.044.67——
P/B Ratio3.541.811.932.011.162.02——
P/FCF24.7925.0332.61—————
P/OCF36.5418.8426.05—33.25331.00——

P/E links to full P/E history page with 30-year chart

LFST EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—1.902.503.132.474.69——
EV / EBITDA33.0334.2179.44—————
EV / EBIT218.90112.34——————
EV / FCF—24.5336.47—————

LFST Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin32.4%32.4%32.2%28.6%27.6%30.2%35.6%29.4%
Operating Margin1.7%1.7%-2.5%-17.9%-24.5%-42.9%4.1%7.2%
Net Profit Margin0.7%0.7%-4.6%-17.6%-25.1%-46.0%-10.1%2.7%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE0.7%0.7%-4.0%-12.6%-14.1%-24.2%-9.2%—
ROA0.4%0.4%-2.7%-8.7%-10.5%-17.6%-4.1%2.0%
ROIC1.1%1.1%-1.3%-7.6%-9.2%-14.8%1.8%—
ROCE1.3%1.3%-1.7%-9.7%-11.0%-17.3%1.8%6.8%

LFST Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.130.130.340.360.320.100.37—
Debt / EBITDA2.462.4612.33———7.883.72
Net Debt / Equity—-0.040.230.300.240.010.35—
Net Debt / EBITDA-0.69-0.698.40———7.473.55
Debt / FCF—-0.503.86————27.74
Interest Coverage2.062.06-1.17-8.74-10.68-7.56-1.012.46

Net cash position: cash ($249M) exceeds total debt ($194M)

LFST Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio1.651.651.371.111.332.281.000.50
Quick Ratio1.651.651.371.111.331.961.000.50
Cash Ratio0.990.990.680.390.621.270.250.06
Asset Turnover—0.650.590.500.400.350.240.76
Inventory Turnover—————12.24——
Days Sales Outstanding—24.5338.5243.4443.1054.3042.2932.86

LFST Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield1.3%0.3%——————
FCF Yield4.0%4.0%3.1%—————
Buyback Yield0.0%0.0%0.0%0.0%0.1%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.1%0.0%——
Shares Outstanding—$391M$379M$367M$355M$328M$374M$374M

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Clinician wage inflation pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Pricing Future Margin Expansion

Based on reported figures, LFST trades at a trailing P/E of 76.61 and EV/EBITDA of 33.78, multiples that sit far above the 6.45 to 23.24 EV/EBITDA range of its healthcare peers and imply substantial future growth is already priced in.

The market appears to value LFST as a high-growth services platform rather than a traditional outpatient operator, which is consistent with a forward P/E of 86.81 implying earnings expansion well beyond current levels. With trailing operating margins still near 1.8% on a full-year basis, the multiple depends heavily on sustained margin maturation rather than present earnings power. Investors should monitor whether quarterly margin gains persist, since any stall would leave little valuation cushion.

Adjusted Margins Diverge From Reported Earnings

According to reported quarterly figures, LFST's operating margin rose from negative 0.9% in Q2 2025 to 7.0% in Q2 2026, yet its net margin of 5.4% and stock-based compensation near $19.7M suggest a meaningful gap between headline and economic profitability.

The expansion from negative to mid-single-digit operating margins over four quarters indicates genuine operating leverage as SG&A grew far slower than revenue. However, the persistent gap between reported operating margins and the cited Adjusted EBITDA margin of roughly 15% implies that non-cash compensation and other excluded items absorb a large share of operating profit. Operating margin is therefore the more conservative measure of earning power for this business.

Debt Reversal Reverses Deleveraging Trend

As reported in financial statements, LFST's debt-to-equity ratio climbed from 0.14 in Q2 2026 to 0.31 in Q3 2026 after total debt rose from roughly $200.7M to $461.0M, reversing a multi-year deleveraging path.

Coverage metrics have improved sharply, with interest coverage reaching 12.00 in Q3 2026 against near-zero coverage in 2024, which suggests debt service is currently comfortable. The rapid rise in borrowing after a sustained paydown, however, warrants investigation into its purpose, whether acquisitions or working capital needs. Debt-to-EBITDA rising to 9.60 in the latest quarter indicates that leverage relative to earnings has tightened even if absolute interest burden remains manageable.

Returns Recovering From Near-Zero Baseline

Based on reported figures, LFST's ROIC improved from negative 0.6% in Q2 2024 to 1.6% in Q2 and Q3 2026, a recovery that remains well below the 12.3% ROIC reported by Universal Health Services.

The trajectory points to genuine compounding from a very low base, driven primarily by margin recovery rather than capital efficiency gains, since asset turnover has stayed roughly flat near 0.2x. A goodwill-heavy balance sheet of roughly $1.3B in goodwill against $2.2B in total assets means invested capital is substantial relative to current earnings. Returns will need to climb considerably before they justify the capital base and the premium valuation.

Lagging Peers on Returns, Leading on Growth

Based on reported peer figures, LFST's 1.5% ROE and 4.9% net margin compare unfavorably with Ensign Group's 16.6% ROE and Option Care Health's 16.4%, though LFST's recent 26% revenue growth exceeds most of this group.

The gap in returns appears largely structural, reflecting LFST's labor-intensive model and substantial acquisition-related goodwill that dilutes return metrics relative to asset-light peers. Its growth profile is a clear point of differentiation, but the market is paying a valuation premium for that growth rather than for current profitability. Whether the returns gap narrows depends on whether margin expansion proves durable.

Margin Gains May Not Survive Wage Pressure

Based on reported figures, the most commonly misapplied metric here is EV/EBITDA, which appears to flatter LFST's valuation by excluding the stock-based compensation and clinician costs that drive its economic earnings.

Because labor is the dominant cost and stock-based compensation of $19.7M nearly equaled Q2 2026 net income of $23.6M, EBITDA-based multiples may overstate true cash earning power. Operating cash flow and free cash flow after SBC offer a more conservative lens, though quarterly free cash flow margins have been volatile, ranging from 4.9% to 21.7%. Investors should monitor clinician retention and whether margin improvement holds once wage inflation and SBC are treated as real costs.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus & Technical Research Suite
Open LFST Terminal

LFST Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LFST — Frequently Asked Questions

Quick answers to the most common questions about buying LFST stock.

What is LifeStance Health Group, Inc.'s P/E ratio?

LifeStance Health Group, Inc.'s current P/E ratio is 74.9x. This places it at the 50th percentile of its historical range.

What is LifeStance Health Group, Inc.'s EV/EBITDA?

LifeStance Health Group, Inc.'s current EV/EBITDA is 33.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 56.8x.

What is LifeStance Health Group, Inc.'s ROE?

LifeStance Health Group, Inc.'s return on equity (ROE) is 0.7%. The historical average is -10.6%.

Is LFST stock overvalued?

Based on historical data, LifeStance Health Group, Inc. is trading at a P/E of 74.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are LifeStance Health Group, Inc.'s profit margins?

LifeStance Health Group, Inc. has 32.4% gross margin and 1.7% operating margin.

How much debt does LifeStance Health Group, Inc. have?

LifeStance Health Group, Inc.'s Debt/EBITDA ratio is 2.5x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.